anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: This study aims to explore the application value of vacuum sealing drainage (VSD) technology in the treatment of incision infection dehiscence after surgery in patients with stage II-III colorectal cancer and analyze its impact on prognosis.
METHODS: This retrospective study included patients who experienced incision infection dehiscence after surgery for colorectal cancer between February 2014 and August 2019. Clinical and pathological data, short-term outcomes, and long-term outcomes were compared between the traditional group and the VSD group.
RESULTS: A total of 97 patients were included in this study. There was no significant difference in clinical and pathological data between the traditional group and the VSD group (P > 0.05). The VSD group had fewer dressing changes, lower pain scores during dressing changes, and better granulation tissue growth grading than the traditional group, with statistical significance (P < 0.05). The VSD group started adjuvant chemotherapy earlier and had a higher proportion of ≥4 cycles of chemotherapy. The three-year overall survival rate in the VSD group was better than the traditional group, but the difference was not statistically significant (P > 0.05).
CONCLUSION: The application of VSD technology can promote granulation tissue growth, accelerate incision healing, and facilitate patients to complete subsequent adjuvant chemotherapy. However, further verification of its long-term impact on prognosis requires longer-term follow-up results.
Oxaliplatin starting dose 30 mg/m\^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m\^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
The lamellar system can be e.g. incorporated into a vessel of the type usually used in gynaecology for closing the cervix (e.g. a cap, capsule etc) and may consist of lamellae arranged opposite each other or concertina-fashion. The distance between the lamellae should be such that the high-density medium (which may be e.g. a conventional physiological fluid contg. innocuous density-increasing additives) is prevented by capillary force from flowing out. The new appts. separates out Y-sperm, so that the sex of offspring can be predetermined, e.g. in animal rearing or in human family planning. The appts. can be used in situ, e.g. placed in the cervix of the female animal to be impregnated with the sepd. sperm.
After being informed about the study and potential risks, written consent will be obtained by the investigators. Twenty participants will be recruited for this randomized, experimental study with a two-group longitudinal, pre-posttest, linear association study design to measure attention levels and off-task behaviors. All participants will attend a total of four sessions. The investigator, a registered, licensed occupational therapist, will lead all intervention sessions utilizing a set protocol. Participants will complete an intake session to determine baseline fine motor skills for developmentally appropriate tasks (DAT) before being randomly assigned to either the control group or the SenPlay intervention group. The control group will engage in spontaneous, free play with the supervising only for safety within the sensorimotor gym (see image 1) for 15 minutes, prior to the assessment of off-task behaviors during 10 minutes of DAT. The intervention group will engage in 15-minutes of SenPlay intervention, followed by assessment of off-task behaviors during 10 minutes of DAT. The 10 minutes of DAT will be coded at the beginning of each 15 second interval (Wood et al., 2016) for a total of 40 observation periods. The percentage of on and off-task behaviors will be calculated. Two coders, blinded to the group assignment will code session. Prior to the study, both coders will achieve a reliability of at least 95% accuracy in training sessions.
A composition which elicits antibodies to most (e.g., greater than 95 %) of the known variants of Tat protein of HIV 1 of both the B and non B clades contains at least two variants of a peptide or polypeptide of the formula: R1 Asp Pro Y7 Leu X9 Pro Trp Z12 R2 [SEQ ID NO:8]. According to this formula, Y7 is Arg, Lys, Ser or Asn; X9 is Glu or Asp; Z12 is Lys or Asn; R1 is hydrogen, a lower alkyl, a lower alkanoyl, or a sequence of between 1 to about 5 amino acids, optionally substituted with a lower alkyl or lower alkanoyl; and R2 is a free hydroxyl, an amide, or a sequence of one or up to about 5 additional amino acids, optionally substituted with an amide. In this composition, at least one of the two variants contains Arg at Y7 and Lys at Z12, and in at least a second of the two variants Y7 is Asn and Z12 is Asn. Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, associated in multiple antigenic peptides or as part of recombinant proteins. The addition to this combination of other optional immunogens can provide other compositions useful in eliciting primate anti Tat antibodies which cross react with multiple strains and variants of HIV 1 Tat protein. Vaccinal and pharmaceutical compositions can contain the primate antibodies induced by the peptide compositions for use in passive therapy. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.
30,402-00 .DELTA.23-LL-F28249 COMPOUNDS                            ABSTRACT OF THE INVENTION The present invention relates to novel deriva-tives of LL-F28249 compounds wherein the 23-hydroxy group is eliminated to introduce a double bond at the 23,24 position.  These resulting derivatives are .DELTA.23-LL-F28249 compounds.  These LL-F28249 precursor compounds prefera-bly are derived via a controlled microbiological fermen-tation of Streptomyces cyaneogriseus subsp. noncyanogenus having deposit accession number NRRL 15773.   The novel derivatives of the present invention possess activity as anthelmintic, ectoparasitic, insecticidal, acaricidal and nematicidal agents.  They also are useful in areas of human and animal health and in agricultural crops.
The invention belongs to the field of medicinal preparations, and relates to a decataxel self-microemulsifying composition for injection and a preparation method thereof. The decataxel self-microemulsifying preparation comprises the following components by weight percentage: 1 to 20 percent of decataxel, 5 to 60 percent of oil phase, 10 to 90 percent of emulsifier, 1 to 30 percent of coemulsifier, and 0 to 10 percent of additive. The preparation method comprises the following steps: mixing the decataxel, the oil phase, the emulsifier, the coemulsifier and a stabilizer; performing ultrasonic treatment; stirring the mixture at a temperature of between 20 and 80 DEG C to ensure that the mixture is completely dissolved; and mixing evenly to obtain the composition. The self-microemulsion can be directly used and can also be diluted into products of any steady concentration to use by adding the moisture in any proportion. The composition reaches a human body through injection or oral administration, can spontaneously form a microemulsion with nanometer particle size when encountering body fluid, obviously improve the solubility of medicaments, increase the stability of the medicaments, and improve the bioavailability. The composition has the advantages of simple preparation process, high production efficiency, steady product quality, and easy industrialized large-scale production.
BACKGROUND: The aim of this retrospective study was to examine the risk factors of positive lower respiratory tract cultures and to investigate whether nosocomial infections are common in patients with positive lower respiratory tract cultures.
METHODS: We enrolled 86 patients diagnosed with influenza A-related critical illness who were treated at Fuzhou Pulmonary Hospital of Fujian in China between 1st October 2013 and 31st March 2019. The of admission were used to divide the enrolled patients into two groups. Sputum and bronchoalveolar lavage fluid specimens were collected within 48 h after admission for culture. All samples were cultured immediately after sampling. Nosocomial infections are defined as any symptom or sign of pulmonary infiltration, confirmed by X-ray, after 5 days of admission and positive results from one or more cultures.
RESULTS: The average age of this cohort was (54.13 ± 16.52) years. Based on the culture results, Staphylococcus aureus and Candida albicans had the highest positive rates (3.40% (3/86) and 20.90% (18/86), respectively). In patients with positive lower respiratory tract cultures, the incidence of nosocomial infection was 73.30% (22/30) five days after admission. However, the incidence of nosocomial infection was lower (42.80%, 24/56) in patients with negative lower respiratory tract cultures. Hemoptysis, systolic pressure at admission, and blood urea nitrogen level at admission were all independent risk factors for positive lower respiratory tract cultures within 48 h of admission.
CONCLUSION: Our data showed that a significant proportion of patients with pneumonia exhibited co-infections with bacteria or fungi within five days of hospital admission. Hemoptysis, systolic pressure, and blood urea nitrogen levels at admission emerged as the key risk factors. These findings underscore the necessity of closely monitoring patients with influenza infection, particularly for positive bacterial or fungal cultures within the initial 48 h of admission.
The invention discloses a traditional Chinese medicine for treating globus hysteriocus diseases. The medicine is characterized by being a decoction comprising the following raw material medicines: caulis lonicerae, radix scrophulariae, orange red, vegetable sponges, semen brassicae, burdocks, radix sophorae subprostratae, dandelions, mangnolia officinalis, platycodon grandiflorum and licorice roots. In the invention, purely natural traditional Chinese medicine raw materials are adopted, and all the components conform to rules of pharmaceutical laws; the traditional Chinese medicine has the effect of curing globus hysteriocus by utilizing the combined effect of all traditional Chinese medicines, contains no chemical sweeteners and has no poison to the human body. The traditional Chinese medicine has slightly sweet taste and no bitter or astringent feels and is convenient to take. Proved by clinical observations of selected cases, after taking the medicine for 3-4 courses of treatment by the usage of twice a day and 100ml each time, patients can be cured, wherein each course of treatment includes 5 days. At present, about 1,000 cases of patients are cured, and the total effective rate is 95 percent, wherein complete recovery is seen as effective.
The goal of this study was to determine the effects of applying random vs. constant constraint force to the non-paretic leg during walking on enhanced use of the paretic leg in individuals post-stroke, and examine the underlying brain mechanisms. Twelve individuals with chronic stroke were tested under two conditions while walking on a treadmill: random vs. constant magnitude of constraint force applied to the non-paretic leg during swing phase of gait using a custom designed robotic system. Leg kinematics, muscle activity of the paretic leg, and electroencephalography (EEG) were recorded during treadmill walking. Paretic step length and muscle activity of the paretic ankle plantarflexors significantly increased after walking with random and constant constraint forces. Cortico-cortical connectivity between motor cortices and cortico-muscular connectivity from the lesioned motor cortex to the paretic ankle plantarflexors significantly increased for the random force condition but not for the constant force condition. In addition, individuals post-stroke with greater baseline gait variability showed greater improvements in the paretic step length after walking with random force condition but not with the constant force condition. In conclusion, application of random constraint force to the non-paretic leg may enhance the use of the paretic leg during walking by facilitating cortical drive from the lesioned motor cortex to the paretic ankle plantarflexors. Results from this study may be used for the development of constraint induced locomotor intervention approaches aimed at improving locomotor function in individuals after stroke.
BACKGROUND: A subset of individuals (10-20%) experience post-COVID condition (PCC) subsequent to initial SARS-CoV-2 infection, which lacks effective treatment. PCC carries a substantial global burden associated with negative economic and health impacts. This study aims to evaluate the association between plasma taurine levels with self-reported symptoms and adverse clinical outcomes in patients with PCC.
METHODS AND FINDINGS: We analyzed the plasma proteome and metabolome of 117 individuals during their acute COVID-19 hospitalization and at the convalescence phase six-month post infection. Findings were compared with 28 age and sex-matched healthy controls. Plasma taurine levels were negatively associated with PCC symptoms and correlated with markers of inflammation, tryptophan metabolism, and gut dysbiosis. Stratifying patients based on the trajectories of plasma taurine levels during six-month follow-up revealed a significant association with adverse clinical events. Increase in taurine levels during the transition to convalescence were associated with a reduction in adverse events independent of comorbidities and acute COVID-19 severity. In a multivariate analysis, increased plasma taurine level between acute and convalescence phase was associated with marked protection from adverse clinical events with a hazard ratio of 0.13 (95% CI: 0.05-0.35; p<0.001).
CONCLUSIONS: Taurine emerges as a promising predictive biomarker and potential therapeutic target in PCC. Taurine supplementation has already demonstrated clinical benefits in various diseases and warrants exploration in large-scale clinical trials for alleviating PCC.
AIMS: Endothelial-mesenchymal transition (EndMT) is a crucial pathological process contributing to cardiac fibrosis. Bradykinin has been found to protect the heart against fibrosis. Whether bradykinin regulates EndMT has not been determined.
MATERIALS AND METHODS: Rats were subjected to ligation of the left anterior descending coronary artery for 1 h and subsequent reperfusion to induce cardiac ischemia-reperfusion (IR) injury. Bradykinin (0.5 μg/h) was infused by an osmotic pump implanted subcutaneously at the onset of reperfusion. Fourteen days later, the functional, histological, and molecular analyses were performed to investigate the changes in cardiac fibrosis and EndMT. Human coronary artery endothelial cells were utilized to determine the molecular mechanisms in vitro.
RESULTS: Bradykinin treatment improved cardiac function and decreased fibrosis following cardiac IR injury, accompanied by ameliorated EndMT and increased nitric oxide (NO) production. In vitro experiments found that bradykinin mitigated transforming growth factor β1 (TGFβ1)-induced EndMT. Significantly, the bradykinin B2 receptor antagonist or endothelial nitric oxide synthase inhibitor abolished the effects of bradykinin on EndMT inhibition, indicating that the bradykinin B2 receptor and NO might mediate the effects of bradykinin on EndMT inhibition.
CONCLUSION: Bradykinin plays an essential role in the process of cardiac fibrosis. Bradykinin preserves the cellular signature of endothelial cells, preventing them from EndMT following cardiac IR injury, possibly mediated by bradykinin B2 receptor activation and NO production.
Oral dysesthesia (OD) is a diagnosis of exclusion that manifests as an unpleasant and abnormal sensation of the oral mucosa without any noticeable oral lesions. Burning sensation is one of the manifestations of OD which may advocate for similar pharmacotherapeutic options to burning mouth syndrome (BMS), resulting in possible adverse events. The aim of these case reports was to illustrate the significance and rationale for the use of oral devices as a mechanical/physical barrier and a safe approach in the management of OD, without experiencing any antagonistic effects from pharmacotherapeutic agents. Two patients with spontaneous and evoked (following dental procedures) OD symptoms in the right posterior mandibular quadrant and anterior hard palatal areas were evaluated. Additionally, their OD symptoms were associated with hyposalivation and taste changes. A thorough history and complete head and neck examination, with the exclusion of oral lesions and systemic conditions, were performed. These patients were previously prescribed topical clonazepam rinses. An in-office trial, with application of orthodontic wax to the affected area, was performed as a preliminary test in order to justify the fabrication of an oral device for possible symptomatic relief. Conclusion: The case reports demonstrated significant improvement of OD symptoms and amelioration of pain following fabrication of oral devices in two patients with no undesirable effects from pharmacotherapy. Additionally, the oral devices aided as a mechanical/physical barrier, potentially exerting a placebo effect while facilitating an improved quality of life. Furthermore, the cost-effectiveness and ease of fabricating the oral device has been advantageous over other systemic medications. This encourages the need for a detailed prospective study.
E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Borg scale, and exercise logs), and 3) telephone coaching by cardiac rehabilitation (CR) staff. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months.
OBJECTIVE: To examine first attempt success and overall success of real-time ultrasound guided peripheral arterial cannulation in infants.
STUDY DESIGN: Retrospective review of 477 ultrasound guided peripheral arterial cannulations in infants less than 1 year of age. Procedural and patient characteristics were evaluated to better understand factors related to procedural success.
RESULTS: Ultrasound guided peripheral arterial cannulation had a first attempt success rate of 65% and an overall success rate of 86%. Success rates significantly differed by arterial location (p < 0.001). First attempt success and overall success were highest in the radial artery (72%, 91%) and lowest in the posterior tibial artery (44%, 71%). Success was more likely with greater age and greater weight (p = 0.006, p = 0.002).
CONCLUSION: Success rates are high when using a real-time ultrasound-guided technique for peripheral arterial cannulation in infants. An infant's weight and selected artery are strong predictors of success when performing peripheral arterial cannulation. The use of procedural ultrasound may reduce unnecessary attempts and minimize procedure-related harm.
PURPOSE:To cosmetic, consisting of a water-in-oil type emulsion prepared by adding a colorant to a composition consisting of an oleophilic surfactant, an oil, a polyhydric alcohol having 3 or more OH groups and water, resistant to the make-up disorder, and having a good touch. CONSTITUTION:A cosmetic consisting of a water-in-oil type emulsion prepared by adding 0.5-40pts.wt., based on 100pts.wt. composition consisting of 1- 20pts.wt. oleophilic surfactant, e.g. a polyglycerol, monoester of glycerolpyroglutamic acid with a fatty acid, 2-40pts.wt. oiling agent, 1.5-60pts.wt. polyhydric alcohol having 3 or more hydroxyl groups in the molecule and 20-85pts.wt. water, colorant to the composition. 0.1-20pts.wt., based on the aqueous phase, water-soluble multivalent metallic salt of an inorganic acid or water-soluble organic acid or a salt thereof may be added to the resultant emulsion. Thus, the stability to temperature is further improved.
FIELD: pharmacy. SUBSTANCE: composition has substance(s) showing secondary irritant effect and antagonist(s) of substance P in pharmaceutically acceptable medium. Antagonist of substance P - compounds containing heterocycles, nitrogen-containing compounds having one or some benzene cycles, peptides and others. Preferable content of antagonist of substance P is 0.0001-0.1 wt.-%. Pharmaceutically acceptable medium: aqueous, aqueous-spirituous or oily solutions, emulsion water-in-oil, microemulsion, aqueous gel, anhydrous gel, serum, vesicular dispersion. Method involves addition of an antagonist of substance P to a composition containing a compound showing secondary irritant effect in pharmaceutically acceptable medium. Composition can be used for treatment of patients with acne, psoriasis, skin lymphomas, ulcers and others and especially for patients with irritant and/or reactive skin. EFFECT: enhanced effectiveness of composition, decreased irritant effect of some active, pharmaceutical or dermatological substances containing in similar compositions. 17 cl, 1 tbl, 10 ex
Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention relates to a recombinant trichosanthin combined nanometer preparation and a preparation method and application thereof. The method comprises the following steps: expressing and purifying recombinant trichosanthin (rTLM) plasmid to obtain ribosome-inactivating eggrTLM with white (RIP) activity. BSA, DMEM medium, mnCl  2  ·4H  2  O and CaCl  2  And (3) mixing and culturing the aqueous solution to prepare the BSA-MnCaP nano-particles. Then, the BSA-MnCaP nano-particles are used as a carrier to load rTLM, so that the nano-preparation is prepared. The preparation process of the nano preparation provided by the invention is simple and convenient to operate. The nano preparation prepared by the invention adopts BSA-MnCap nanoparticle carrier to deliver rTLM, so that the effect of effectively inhibiting tumor and simultaneously solving the problem of systemic toxicity to mice caused by directly exposing rTLM is achieved, and the PH response performance of the calcium phosphate nanoparticle can realize the controllable delivery of rTLM at tumor positions.